Activist S.H.N. Asks Tel Aviv Court to Force Board Vote at December 21 AGM
PRFX is trading near its 52-week low of $0.604 (0.6% above the low) on light trading volume (0.1× avg).
Summary
Activist holder S.H.N. asked a Tel Aviv court on November 18 to force PRF Technologies to put its board-removal and director-election proposals on the December 21 annual meeting agenda, after the company excluded them and left a targeted director up for re-election.
Key Events · Corporate Governance and Compliance · PRFX
-
Court Motion Filed to Force Agenda Vote
On November 18, 2026, S.H.N. moved to amend its pending Petition so the Tel Aviv court would direct PRF to add its resolutions to the December 21, 2026 Annual Meeting agenda and publish amended proxy materials.
-
Company Excluded Proposals, Kept Targeted Director
PRF's November 13, 2026 meeting notice refers to the pending Petition but omits its subject matter, while including the re-election of Mr. Asaf Shavit — one of the three directors S.H.N. wants removed.
-
Three Replacement Nominees Proposed
S.H.N. seeks removal of Dr. Ehud Geller, Mr. Efi Cohen-Arazi and Mr. Asaf Shavit, and election of Margarita Hirsch Malahovich (Class I), Liat Katzman (Class II) and Amos Pickel (Class III).
-
5.716% Stake Backs the Demand
S.H.N. holds 200,000 ordinary shares, about 5.716% of the 3,499,144 shares outstanding as of November 12, 2026 — above the 5% threshold for an agenda demand under Israeli regulations.
Analysis · PRFX · Life Sciences
S.H.N. holds 200,000 shares, or 5.716% of PRF, and has been trying since September to replace most of the board. The company scheduled its annual meeting for December 21 but left S.H.N.'s removal and election proposals off the agenda while putting one targeted director, Asaf Shavit, up for re-election. S.H.N. demanded inclusion on November 15, got no confirmation by its November 17 deadline, and on November 18 asked the court to order the resolutions onto the agenda. The fight now runs on two tracks at once — the courtroom and the December 21 shareholder vote — and the outcome decides who controls a company that is simultaneously fighting a Nasdaq delisting notice and planning a 5-to-1 reverse split at that same meeting.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRFX was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $0.60 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.